Please assess the completion status of the following clinical trial:

Trial Title: A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has Type 2 Diabetes (T2DM)~* Participant is either: Not on an oral antihyperglycemic medication for at least 6 weeks; on a single oral antihyperglycemic medication that is not a peroxisome proliferator-activated gamma (PPAR-gamma) agonist (e.g. Avandia); OR on a combination of no more than two antihyperglycemic medications that are not PPAR-gamma) agonists~* Participant has not received insulin for at least 6 months~* Participant has not been treated with a PPAR-gamma agonist for at least 12 weeks~* Participant has been a nonsmoker for at least 6 months~* Female participants who are non-pregnant and highly unlikely to conceive due to surgical sterilization, post-menopausal status, not heterosexually active, or willing to use 2 birth control methods~Exclusion Criteria:~* Participant has a history of stroke, seizures, or neurological disorders~* Participant cannot tolerate insulin or propranolol~* Participant has a history of asthma, emphysema or chronic bronchitis~* Participant is on a weight loss program that is not in the maintenance phase or has been treated with a weight loss medication within 8 weeks of screening~* Participant is on or may require treatment with drugs that affect the immune system or with corticosteroids~* Participant has a history of heart failure or coronary artery disease~* Participant has a history of uncontrolled high blood pressure~* Participant is Human Immunodeficiency (HIV), hepatitis B or hepatitis C positive~* Participant has a history of Type 1 diabetes~* Participant has a history of hypoglycemia unawareness documented by a blood glucose concentration \< 55 mg/dL (3.1 mol/L) without symptoms of hypoglycemia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Propanolol + Placebo > Propanolol + MK0893 (Type: EXPERIMENTAL): Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893-matched placebo was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893 on Day 21 (Visit 8).
- Propanolol + MK0893 > Propanolol + Placebo (Type: PLACEBO_COMPARATOR): Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893 was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893-matched placebo on Day 21 (Visit 8).

Based on this trial design, predict the completion outcome and termination type (if applicable).